Glimepiride

Research use only, not for human use.

Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action.

Glimepiride is the first III generation sulphonyl urea it is a very potent sulphonyl urea with long duration of action. (In Vivo):Glimepiride (Glimperide) is a new sulfonylurea. After oral administration of Hoe 490 to rabbits, blood glucose was lowered 3.5 times more than after glibenclamide (HB 419) and after intravenous administration, 2.5 times more. Glimepiride (Glimperide) decreased extracellular Aβ40 and Aβ42 levels. glimepiride may serve as a promising drug for the treatment of AD associated with diabetes. Glimepiride (Glimperide) was generally associated with lower risk of hypoglycemia and less weight gain compared to other sulfonylureas. Glimepiride (Glimperide) use may be safer in patients with cardiovascular disease because of its lack of detrimental effects on ischemic preconditioning.

——

——

HOE 490

Cell Cycle/DNA Damage

Potassium Channel

SUR1| SUR2A| SUR2B

Metabolic Disease

——

93479-97-1

490.62

C24H34N4O5S

>98% (HPLC)

DMSO: 11 mg/mL (22.42 mM)

CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C

4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide

(-20℃)

With Ice Pack

≥ 2 years